Tajiri K, Ito H, Kawai K, Kashii Y, Hayashi Y, Murayama A, Minemura M, Takahara T, Shimizu Y, Yasuda I. Direct-acting antivirals for hepatitis C virus-infected patients with hepatocellular carcinoma. World J Hepatol 2022; 14(6): 1190-1199 [PMID: 35978673 DOI: 10.4254/wjh.v14.i6.1190]
Corresponding Author of This Article
Kazuto Tajiri, MD, PhD, Associate Professor, Department of Gastroenterology, Toyama University Hospital, 2630 Sugitani, Toyama 930-0194, Japan. tajikazu@med.u-toyama.ac.jp
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Retrospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Kazuto Tajiri, Yuka Hayashi, Aiko Murayama, Masami Minemura, Terumi Takahara, Ichiro Yasuda, Department of Gastroenterology, Toyama University Hospital, Toyama 930-0194, Japan
Hiroyuki Ito, Department of Gastroenterology, Takaoka Municipal Hospital, Takaoka 933-8550, Japan
Kengo Kawai, Yukihiro Shimizu, Gastroenterology Center, Nanto Municipal Hospital, Nanto 932-0211, Japan
Yoshiro Kashii, Department of Gastroenterology, Saiseikai Toyama Hospital, Toyama 931-8533, Japan
Author contributions: Tajiri K designed and performed the research and wrote the paper; Ito H, Kawai K, Murayama A, Hayashi Y, Minemura M, Takahara T, and Shimizu Y contributed to the management of patients; Shimizu Y and Yasuda I supervised the work.
Institutional review board statement: This study was reviewed and approved by the ETHICs Committee of Toyama University.
Informed consent statement: Patients were not required to give informed consent to the study because the analysis used anonymous clinical data that were obtained after each patient had agreed to treatment with confirmed written consent.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Kazuto Tajiri, MD, PhD, Associate Professor, Department of Gastroenterology, Toyama University Hospital, 2630 Sugitani, Toyama 930-0194, Japan. tajikazu@med.u-toyama.ac.jp
Received: January 12, 2022 Peer-review started: January 12, 2022 First decision: March 16, 2022 Revised: March 18, 2022 Accepted: May 28, 2022 Article in press: May 28, 2022 Published online: June 27, 2022
ARTICLE HIGHLIGHTS
Research background
Treatment with direct-acting antivirals (DAAs) has provided many benefits to hepatitis C virus (HCV)-infected patients. Hepatocellular carcinoma (HCC) development after treatment with DAAs remains a serious issue.
Research motivation
The effect of DAA treatment on the risk of HCC development is an important clinical question.
Research objectives
To clarify the risk of HCC development after DAA treatment in patients HCV-infected patients at high risk for HCC development.
Research methods
HCC occurrence after DAA treatment was retrospectively evaluated in patients with and without a history of HCC.
Research results
The frequency of HCC recurrence/occurrence was similar before and after treatment with DAAs. The number of HCC occurrences before DAA treatment was an independent risk factor for HCC recurrence/occurrence.
Research conclusions
HCV-infected patients with a history of multiple HCCs should be monitored carefully for HCC recurrence.
Research perspectives
An effective screening method should be established for patients at high risk of HCC recurren- ce/occurrence.
